title: The impact of aprotinin on renal function after liver transplantation: an analysis of 1,043 patients.
abstract: Renal dysfunction is frequently seen after orthotopic liver transplantation (OLT). Aprotinin is an antifibrinolytic drug which reduces blood loss during OLT. Recent studies in cardiac surgery suggested a higher risk of postoperative renal complications when aprotinin is used. The impact of aprotinin on renal function after OLT, however, is unknown. In 1,043 adults undergoing OLT, we compared postoperative renal function in patients who received aprotinin (n = 653) or not (n = 390). Using propensity score stratification (C-index 0.82) and multivariate regression analysis, aprotinin was identified as a risk factor for severe renal dysfunction within the first week, defined as increase in serum creatinine by >or= 100% (OR = 1.97, 95% CI = 1.14-3.39; p = 0.02). No differences in renal function were noted at 30 and 365 days postoperatively. Moreover, no significant differences were found in the need for renal replacement therapy (OR = 1.52, 95% CI = 0.94-2.46; p = 0.11) or in 1-year patient survival rate (OR = 1.14, 95% CI = 0.73-1.77; p = 0.64) in patients who received aprotinin or not. In conclusion, aprotinin is associated with a higher risk of transient renal dysfunction in the first week after OLT, but not with a higher need for postoperative renal replacement therapy or an increased risk of mortality.
authors: Section Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
authors: N
authors: N
authors: Warnaar
authors: S V
authors: SV
authors: Mallett
authors: M T
authors: MT
authors: de Boer
authors: N
authors: N
authors: Rolando
authors: A K
authors: AK
authors: Burroughs
authors: M W N
authors: MW
authors: Nijsten
authors: M J H
authors: MJ
authors: Slooff
authors: K
authors: K
authors: Rolles
authors: R J
authors: RJ
authors: Porte
mesh_terms: D000328:Adult; D007611:Aprotinin / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology*; D007677:Kidney Function Tests; D008107:Liver Diseases / Q000145:classification / Q000601:surgery; D016031:Liver Transplantation / Q000401:mortality / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011183:Postoperative Complications / Q000139:chemically induced; D012044:Regression Analysis; D017582:Renal Replacement Therapy; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D006490:Hemostatics; D007611:Aprotinin; D003404:Creatinine